APTO Aptose Biosciences Inc.

1.83
-0.02  -1%
Previous Close 1.85
Open 1.84
Price To Book 5.47
Market Cap 73655875
Shares 40,249,112
Volume 103,226
Short Ratio
Av. Daily Volume 307,346

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1b clinical hold released June 29, 2018. First patient of re-initiation announced November 26, 2018. To be completed in 2019.
APTO-253
Acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS)
Phase 1 trial to be initiated 2Q 2019.
CG-806
Chronic lymphocytic leukemia (CLL/SLL) or non-Hodgkin lymphomas (NHL)

Latest News

  1. Aptose to Present at the H.C. Wainwright Annual Global Life Sciences Conference
  2. Aptose Announces FDA Allowance of Investigational New Drug Application for CG-806
  3. Aptose Biosciences: 4Q Earnings Snapshot
  4. Aptose Reports Results for the Fourth Quarter and Year Ended December 31, 2018
  5. Aptose to Participate in Upcoming Investor Conferences in March 2019
  6. Aptose Biosciences and CrystalGenomics Announce Issuance of Australian Patent for CG-806
  7. Aptose to Present New CG-806 and APTO-253 Data at the 2019 AACR Annual Meeting
  8. Aptose To Release Fourth Quarter and Year End December 31, 2018 Financial Results and Hold Conference Call on March 12, 2019
  9. Aptose Biosciences Submits IND Application for CG-806
  10. Will Difficult Comparison Hurt Bio-Rad's (BIO) Q4 Earnings?
  11. Will Hospice Strength Show on Amedisys' (AMED) Q4 Earnings?
  12. Aptose to Present at the 8th Annual SVB Leerink Global Healthcare Conference
  13. Factors of Influence in 2019, Key Indicators and Opportunity within The TJX Companies, Nasdaq, Werner Enterprises, Global Ship Lease, Domo, and Aptose Biosciences — New Research Emphasizes Economic Growth
  14. Aptose Biosciences to Present at Biotech Showcase™ 2019 Conference
  15. Aptose Biosciences Sees Hammer Chart Pattern: Time to Buy?
  16. Aptose Presents Highlights From CG-806 KOL Event
  17. OHSU and Aptose Present New CG-806 Preclinical Data at ASH 60th Annual Meeting
  18. Aptose Presents New Preclinical Data on CG-806 PAN-FLT3/PAN-BTK Inhibitor at ASH 60th Annual Meeting
  19. Aptose Biosciences Doses First Patient in Re-Initiation of Phase 1b Clinical Study of APTO-253 in Relapsed or Refractory Hematological Malignancies
  20. Aptose to Participate in Upcoming Investor Conferences, Host Key Opinion Leader Event, and Present Data at the Upcoming ASH Meeting